Abstract
Docetaxel and paclitaxel both belong to the taxane family and block depolymerization of tubulin. In ovarian carcinoma, the development of docetaxel has followed a rational path over the last 10 years. Here, we review data from Phase I and II studies that have established docetaxel–platinum compound combinations as valuable options in the treatment of ovarian cancer. A large international Phase III study has proved that the docetaxel–carboplatin combination is at least equivalent to the standard paclitaxel–carboplatin regimen in the first-line setting for stage III–IV ovarian carcinomas.
Keywords::
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.